Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in China / NCT06342440
Recruiting Observational

Early Detection of Advanced Adenomas and Colorectal Cancer

NCT06342440 · tracked via the Priya Life Science China tracker
Sponsor
City of Hope Medical Center
Phase
Observational
Started
2020-03-15
Last updated
2026-07-07

Condition(s) studied

Colorectal CancerColorectal NeoplasmsColorectal PolypColorectal AdenocarcinomaColorectal DisordersColorectal DysplasiaColorectal Cancer Stage IColorectal Cancer Stage IIColorectal Cancer Stage IIIColorectal Cancer Stage IVColorectal Neoplasms MalignantColorectal Serrated AdenocarcinomaColorectal Adenoma With Severe DysplasiaColorectal Adenoma With Mild DysplasiaColorectal Adenoma With Moderate DysplasiaColorectal Adenoma and Carcinoma 1Colorectal Adenomatous PolypColorectal Adenocarcinoma Metastatic in the Liver

Investigational drug(s) / intervention(s)

DENEB

DENEB: A panel of circulating microRNA, whose expression level is tested in cell-free and exosome-derived samples.

Study summary

This study aims to develop a highly sensitive, specific, and cost-effective blood assay for early detection of colorectal adenomas and cancer, using advanced machine learning and state-of-the-art biological analyses.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria: * All individuals included in the study need to have had a colonoscopy at the time of blood sampling. * Received standard diagnostic and staging (as necessary) procedures as per local guidelines, and at least one sample was drawn before receiving any curative-intent treatment. * Received standard pathological and endoscopic diagnosis and assessment for cohort assignment. Exclusion Criteria: * Hereditary colorectal cancer syndromes (identified through genetic testing). * Inflammatory bowel diseases. * Lack of written informed consent.

Primary outcome measure(s)

  • Sensitivity — Through study completion, an average of 1 year
    True positive rate: the probability of a positive test result, conditioned on the individual truly being positive

Trial sites (6)

FacilityCityRegionStatus
City of Hope Medical Center Monrovia California Recruiting
University of California San Diego San Diego California Recruiting
The First Affiliated Hospital of Dalian Medical University Dalian China Recruiting
IRCCS San Raffaele Milan Italy Recruiting
Mie University Mie Japan Recruiting
Barcelona University Barcelona Spain Recruiting

More City of Hope Medical Center trials in China

Stage II/III Colorectal Cancer Recurrence Recruiting

Other trials for the same condition

The Application Value of Spectral CT in the Accurate Staging of Colorectal Cancer Starting soon
Fruquintinib With or Without HAI-FOLFOX for Refractory Colorectal Cancer Recruiting
A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy Recruiting
The Safety and Efficacy of Cetuximab Beta Plus Fruquintinib With or Without Immune Checkpoint Inhibitorrs in First-line Treatment of RAS/BRAF Wild Type Unresectable Metastatic Colorectal Cancer Recruiting
To Evaluate the Tolerability and Pharmacokinetics of TQB2101 for Injection in Patients With Advanced Malignant Tumors Starting soon
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06342440 on ClinicalTrials.gov ↗ ← All trials in China